Immuno-oncology research and innovation: open directory
Communications and Campaigns Manager
This ‘Immuno-oncology research and innovation: open directory’ lists all the projects and opportunities we’ve received in response to our spring 2023 Global Challenge campaign seeking novel academic research and assets in immuno-oncology to treat solid tumour cancers. Each of these projects has been submitted by an academic or research commercialisation professional with the aim of initiating meaningful conversations and partnerships leading to the collaborative development of new interventions.
How to review the projects
A non-confidential summary of each project is hosted on IN-PART’s digital matchmaking platform, Connect, for university-industry collaboration. Set up an account (it’s completely free), log in, and follow the links below.
How to connect with the teams behind them
If you see a project that aligns with your R&D priorities, you can make a request for more information directly through the article on Connect. The academic team or project lead will then send you a response by email.
There are no costs or downstream fees for companies to use IN-PART’s matchmaking platform to connect with universities – it’s maintained by institutional subscriptions.
Immuno-oncology research and innovation: open directory
Content navigation
Technologies
Therapeutics
COBRA1/NELF-B as a Booster for Efficacy of CD8+ T Cell-Based Therapy
George Washington University
Read the project summary
T Cells Targeted Against Multiple Antigens for Cancer Treatment
George Washington University
Read the project summary
Targeting Therapeutic T Cells to Tumor Sites
LMU Munich
Read the project summary
Enabling Technologies for Cellular Therapies of Solid Cancer Entities
LMU Munich
Read the project summary
Carbocyanine Dyes for Photodynamic Therapy in Treating Cancer
Georgia State University
Read the project summary
Detection & Treatment of Melanoma and Lymphoma Cancer using ATR-FTIR Spectroscopy
Georgia State University
Read the project summary
Targeting ART1 to Overcome Immune Resistance in Lung Cancer
Institute of Cancer Research (ICR)
Read the project summary
CAR-T Therapy Development for Breast Cancer and Other Solid Tumours
Institute of Cancer Research (ICR)
Read the project summary
Immunotherapy and Vaccine-based Targeting of Drug Resistance in Homologous Recombination-defective Cancers
Institute of Cancer Research (ICR)
Read the project summary
Targeting Drug-resistant Prostate Cancer with IL-23 Inhibitors
Institute of Cancer Research (ICR)
Read the project summary
IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors
National Cancer Institute
Read the project summary
Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors
National Cancer Institute
Read the project summary
Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors
National Cancer Institute
Read the project summary
Efficacious Fluorinated Cytidine Analog Cancer Therapeutic With Low Toxicity In Animal Studies
National Cancer Institute
Read the project summary
Cancer Immunotherapies That Harness Pre-Existing Antiviral Immunity
National Cancer Institute
Read the project summary
Dendritic Cell-based Therapies for Cancer Treatment
NOVA de Lisboa
Read the project summary
Unique Chemical Class of PARP Inhibitors for use in the Treatment of Cancer and Inflammatory Condition
University of Oulu
Read the project summary
ADP-Ribosylation Inhibitor for Treatment of Cancer
University of Oulu
Read the project summary
Targeted Nanosphere (TNS) Platform for Therapeutic Applications
Children’s Hospital Los Angeles
Read the project summary
T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy
National Cancer Institute
Read the project summary
First-in-Class Therapeutic Targeting Rogue Neutrophil Drivers of Human Diseases
Boston University
Read the project summary
Anti-CD3 Fab to Amplify Antigen-specific T Cell Response for the Treatment of Cancer and Viral Infection
University of Missouri
Read the project summary
Novel Immunoproteases
University of Cape Town
Read the project summary
Novel Photoimmunoconjugates for Use in Photodynamic Therapy
University of Cape Town
Read the project summary
A Microtubuli Modifying Compound
University of Cape Town
Read the project summary
Discovering and Developing Small-molecule Inhibitors of ERAP1
Institute of Cancer Research (ICR)
Read the project summary
Fully Human Anti-mesothelin CAR with Low Immunogenicity for in vivo Persistence of Anti-tumor Engineered T Cells
University of Pennsylvania
Read the project summary
Single Viral Vector for Expression Of Both CAR/TCR and Immune Modulators for Cancer Immunotherapy
University of Pennsylvania
Read the project summary
Tumor Mitochondria Vaccine for the Treatment of Cancer
University of Pennsylvania
Read the project summary
Universal Cancer Vaccine Targeting Tumor Vasculature
University of Pennsylvania
Read the project summary
Targeting the Retinoic Acid Pathway to Bolster Immunotherapy
University of Pennsylvania
Read the project summary
Enhancing the Efficacy of Tumor Immunotherapy by Targeting Endothelin Receptor
University of Pennsylvania
Read the project summary
Biomineralized Tumor Cells as a Personalized Therapeutic Vaccine
University of New Mexico
Read the project summary
Potent And-1 Inhibitors that Suppress Tumor Growth and Overcome Platinum Drug Resistance
George Washington University
Read the project summary
Novel Small Molecules Targeting the NK Cell/Tumour CD96/CD155 Checkpoint for Cancer Therapy
BC Cancer
Read the project summary
Combined Inhibition of Human Plasmacytoid Dendritic Cell Activity during Systemic Lupus Erythematosus (SLE)
Max Planck Society
Read the project summary
Overcoming Disease Persistence in Myeloproliferative Neoplasms (MPN) through Combinatorial Inhibitor Treatment
Max Planck Society
Read the project summary
ADAM10 and ADAM17 Cleave PD-L1 to Mediate PD-(L)1 Inhibitor Resistance
Mayo Clinic
Read the project summary
Cell-Free, Cell-Like Vaccines for Personalized Cancer Immunotherapy
University of California, Irvine
Read the project summary
Diagnostics/biomarkers
Novel Photoimmuno-Theranostics for Detection and Elimination of Skin Cancer Cells
University of Cape Town
Read the project summary
Therapeutic Targets for T-cell Lymphomas and Other Types of Cancer
University of Pennsylvania
Read the project summary
Data-driven approach
Antibody Discovery Platform for CAR-T Cells
University of Pennsylvania
Read the project summary
Target evaluation/visualisation
Immunotherapeutic Targets in Drug-adapted Cancer Cells
University of Kent
Read the project summary
Our campaign launched on the 31st January 2023 and is closing for submissions on Tuesday 14th March. If you’re registered to any of our platforms, you’ll receive more information by email. And to keep updated with our work addressing global challenges you can follow us on Twitter or LinkedIn.
Written by Anabel Bennett. Edited by Frances Wilkinson.
Copyrights reserved unless otherwise agreed – IN-PART Publishing Ltd., 2023: ‘Immuno-oncology research and innovation: open directory’
What is IN-PART?
IN-PART develops digital solutions, curated by in-house STEM experts, that simplify the initial connection between decision-makers in academia and industry. Our goal is to help drive impact from research by matching innovation and expertise on a level playing field globally.
Connect, a digital partnering platform for university-industry collaboration.
An online matchmaking platform used by 250+ universities and research institutes to connect with industry teams in 6,000+ companies to commercialise academic innovations and expertise that are available and seeking collaboration.
Discover, a bespoke scouting service for open innovation.
A bespoke scouting platform used by innovation-driven companies to profile the global landscape of academia across an active network of 2,600+ institutes, either through ‘Industry Calls for Opportunities’ or ‘Request for Proposal’ campaigns that find and confirm potential solutions to specific R&D challenges or requirements.
Header image credit: National Cancer Institute / Unsplash
In-line image credits in order of appearance: Adobe Stock, Testaliza.me / Unsplash, Maxim Hopman / Unsplash, National Cancer Institute / Unsplash